NCT00525707已完成3 期
Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study to Assess the Efficacy, Safety, and Tolerability of Tezosentan in Patients With Acute Heart Failure.
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 735
- 试验地点
- 35
- 主要终点
- Incidence of death or worsening heart failure
研究概览
简要总结
The randomized patients with acute heart failure will be stratified based on the presence or absence of a Swan-Ganz catheter and assigned to receive either tezosentan 5 mg/h for the first 30 minutes and 1 mg/h thereafter or matching placebo in a 1:1 manner. The duration of the treatment is 24 hours up to 72 hours. The duration of the follow-up period is 30 days after treatment initiation for death, re-hospitalizations and SAEs followed by a follow-up period of 5 months for vital status.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients 18 years of age or older.
- •Male or non-breast-feeding, non-pregnant female (only females who are post menopausal, surgically sterile or practicing a reliable method of contraception).
- •Acute heart failure (ischemic or non-ischemic).
- •Randomization within 24 hours of hospitalization (including emergency room stay) for acute heart failure.
- •Dyspnea at rest as assessed by the patient and breathing rate ³ 24/min (measured during 60 seconds).
- •At least two out of the following four criteria: · elevated BNP or N terminal pro-BNP (more than three times the upper limit of normal for the site) in patients not treated with nesiritide,· clinical evidence of pulmonary congestion/edema (e.g., rales or crackles more than a third above bases),· evidence of pulmonary congestion on chest X-ray, · left ventricular systolic dysfunction (EF < 40% or wall motion index £ 1.2 within 12 months prior to randomization).
- •Patients in need of i.v. therapy for acute heart failure and who have received at least one dose of i.v. diuretic within 24 hours prior to study drug initiation (last bolus dose must have been more than 2 hours prior to study drug initiation).
- •Written informed consent.
排除标准
- •Criteria only for patients hemodynamically monitored:
- •Baseline cardiac index > 2.5 l/min/m2 and/or PCWP < 20 mmHg within 6 hours prior to study drug initiation.
- •Criteria for all patients:
- •Patients not receiving i.v. vasodilators (e.g., nitrates, nitroprusside, nesiritide) at baseline: supine systolic blood pressure < 100 mmHg. Patients receiving i.v. vasodilators (e.g., nitrates, nitroprusside, nesiritide) at baseline: supine systolic blood pressure < 120 mmHg.
- •Cardiogenic shock within the last 48 hours or evidence of volume depletion.
- •Ongoing myocardial ischaemia, coronary revascularisation procedure (PCI or CABG) during current admission or planned revascularisation.
- •ST-segment elevation myocardial infarction or administration of thrombolytic therapy.
- •Baseline creatinine ≥ 2.5 mg/dl (221 mmol/l).
- •Baseline hemoglobin < 10 g/dl or a hematocrit < 30%.
- •Hemodialysis, ultrafiltration or peritoneal dialysis within the last 7 days.
- •Heart failure due to active myocarditis, obstructive hypertrophic cardiomyopathy, congenital heart disease, restrictive cardiomyopathy or constrictive pericarditis. Heart failure caused by valvular disease.
- •Acute heart failure associated with uncontrolled hemodynamically relevant atrial fibrillation/flutter or ventricular rhythm disturbances.
- •Acute heart failure secondary to clinical evidence of digoxin toxicity or any other drug-related toxicity.
- •Significant chronic and/or acute lung disease that might interfere with the ability to interpret the dyspnea assessments or hemodynamic measurements (e.g., severe chronic obstructive pulmonary disease or acute pneumonia).
- •Mechanical circulatory or ventilatory support. Prior CPAP use is allowed, if discontinued at least 2 hours prior to study drug initiation.
- •Acute systemic infection/sepsis or other illness with a life expectancy less than 30 days.
- •Coronary artery bypass graft, or other cardiac surgery, or major non-cardiac surgery within the last 30 days.
- •Patients who received another investigational drug within 30 days prior to randomization.
- •Re-randomization in the current study.
- •Any factors that might interfere with the study conduct or interpretation of the results such as known drug or alcohol dependence.
- •Concomitant treatment with cyclosporin A or tacrolimus.
研究组 & 干预措施
1
Experimental
tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
干预措施: tezosentan (Drug)
2
Placebo Comparator
干预措施: tezosentan (Drug)
结局指标
主要结局
Incidence of death or worsening heart failure
时间窗: 7 days following study drug initiation
次要结局
- effect on patient's dyspnea assessment, measured using a visual analog scale(Over first 24 hours)
研究者
研究点 (35)
Loading locations...
相似试验
已完成
不适用
Two-Center, In-Patient, Randomized, Placebo and Active Comparator Evaluation of the Pharmacokinetics (PK) and Safety, Along with Initial Pharmacodynamic (PD) Efficacy of Three Dose Levels of TBS-2 Intranasal Gel Applied Twice-Daily (BID) for up to Three Days in Female Patients with Hypoactive Sexual Desire Disorder (HSDD) or Anorgasmia (ANOR).Hypoactive Sexual Desire Disorder and Anorgasmia100147011004048010013356NL-OMON34282Trimel Biopharma SR48
进行中（未招募）
1 期
Clinical study to evaluate eficacy of Pitolisant for children from 6 to 18 years with narcolepsy with/without cataplexyarcolepsyMedDRA version: 20.0Level: LLTClassification code 10028715Term: Narcolepsy with cataplexySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 22.1Level: LLTClassification code 10048322Term: Narcolepsy aggravatedSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10028713Term: NarcolepsySystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 21.1Level: LLTClassification code 10048323Term: Cataplexy aggravatedSystem Organ Class: 10029205 - Nervous system disordersMedDRA version: 20.0Level: PTClassification code 10007737Term: CataplexySystem Organ Class: 10029205 - Nervous system disordersEUCTR2013-001506-29-ITBIOPROJET PHARMA108
尚未招募
4 期
Multicentre, randomized, double blind, placebo-controlled study to evaluate the effect of pancreatic enzyme replacement therapy on glucose metabolism, nutritional parameters, incretin response and beta-cell function in patients with diabetes mellitus and exocrine pancreatic insufficiencyThe licensing phaseJPRN-UMIN000013022First Department of Internal Medicine, Szeged120
尚未招募
4 期
Multi-center, Randomized, Double Blind and Placebo Controlled Clinical Trial on the Efficacy and Safety of Jinhua Qinggan Granules (JHQG) for the Treatment of COVID-19 Patients.ITMCTR2000003697Center for Bioequivalence Studies and Clinical Research,Beijing Hospital of Traditional Chinese Medicine
进行中（未招募）
不适用
Multi center, double blind, randomized, placebo controlled, active reference, parallel group polysomnography study to assess the efficacy and safety of a 16 day oral administration of ACT 078573 in adult subjects with chronic primary insomnia.EUCTR2007-005194-56-SEActelion Pharmaceuticals Ltd668